BioHermes
BioHermes is a privately held Chinese in-vitro diagnostics company (founded 2006, Wuxi) that sells proprietary boronate affinity HbA1c analyzers and reagents, plus obstetrics and nephrology IVD kits, to hospitals, labs, and home users in China and 200+ countries.
- Company typePrivate
- Founded2006
- HeadquartersWuxi, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioHermes does
BioHermes (无锡博慧斯生物医药科技有限公司) is a privately held Chinese in-vitro diagnostics company founded in 2006 and headquartered in Wuxi, Jiangsu Province. Its core technology is a proprietary boronate affinity liquid chromatography method (covered by 17 patents in 12 countries) used in its flagship Botangping® (博唐平®) HbA1c detection platform, with all instrument models annually re-certified under both NGSP and IFCC traceability programs. The company markets a three-brand portfolio — Botangping® for diabetes/HbA1c testing, TaiAnKang® (泰安康®) for obstetrics (IGFBP-1 and fFN kits for preterm rupture of membranes and preterm labor), and HuiAnKang® (慧安康®) for nephrology (ACR rapid analysis for CKD/DKD) — alongside the Gen2 ITS integrated testing platform.
The business model is hardware-and-consumable IVD sales: BioHermes sells diagnostic analyzers and corresponding reagent kits to hospitals, third-party laboratories, and individual home users, with go-to-market combining direct B2B hospital sales, participation in major domestic and international medical exhibitions (MEDICA, AACC, FIME, CMEF, CACLP, Hospital Expo Indonesia, Medlab Asia), academic conferences (CDS, POCT), and direct-to-consumer channels for home glucose/HbA1c meters. Pricing is not publicly disclosed; customers contact the sales team by email for quotes.
BioHermes reports coverage of 20,000+ hospitals across China and exports to more than 200 countries and regions (including India, South Korea, Italy, Egypt, UAE, Indonesia, Thailand, Algeria and Morocco). The company is recognized as a Jiangsu Province High-tech Enterprise, a Wuxi Gazelle Enterprise, and a provincial 'Specialized, Refined, Distinctive and Novel' (专精特新) enterprise. No external funding rounds, parent company, or public-listing status are disclosed.
BioHermes firmographics
Firmographics- Name
- BioHermes
- Legal name
- 无锡博慧斯生物医药科技有限公司
- Website
- https://biohermes.cn
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioHermes is a privately held Chinese in-vitro diagnostics company (founded 2006, Wuxi) that sells proprietary boronate affinity HbA1c analyzers and reagents, plus obstetrics and nephrology IVD kits, to hospitals, labs, and home users in China and 200+ countries.
- Ownership category
- akta.pro rank
BioHermes industry classification
Industry- Product category
- In-Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)
- akta.pro secondary industries
- Hematology & Coagulation Diagnostics (HLAHAAAB), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where BioHermes is headquartered
LocationHeadquarters
- HQ city
- Wuxi
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
BioHermes business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- In-vitro Diagnostic Instruments and Reagents Sales: BioHermes generates revenue through the sale of medical diagnostic instruments (HbA1c analyzers, blood glucose meters, ACR analyzers, etc.) and their corresponding reagent/consumable kits. The core product line includes the Botangping® HbA1c detection system, with products sold to hospitals, clinics, third-party testing institutions, and individual consumers in China and internationally.
- International Export Revenue: Products exported to more than 200 countries and regions globally, including India, South Korea, Italy, Egypt, UAE, Indonesia, Thailand, and others, generating international sales revenue through distributors and direct institutional sales in foreign markets.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
BioHermes product offering
Product offeringCore offering
BioHermes manufactures and sells in-vitro diagnostic (IVD) instruments and reagents specializing in glycated hemoglobin (HbA1c) detection for diabetes management, plus obstetrics rapid test kits (IGFBP-1, fFN) for preterm labor and premature rupture of membranes diagnosis, and ACR (albumin-to-creatinine ratio) rapid analysis systems for nephrology/CKD screening. The company sells these analyzers and consumables to hospitals, primary healthcare institutions, third-party laboratories, and individual home users across China and 200+ international markets.
Product overview
BioHermes (无锡博慧斯生物医药科技有限公司) is an in-vitro diagnostic (IVD) company established in 2006, specializing in chronic disease and women's health diagnostics. The company offers three major product brands: 博唐平® for diabetes/HbA1c testing (including BH60 HPLC analyzer, four-channel and single-channel automated analyzers, handheld detectors, A1C-EXP M13, combination glucose/HbA1c meters, blood glucose meters, and hospital blood glucose management systems), 泰安康® for obstetrics/gynecology products (IGFBP-1 and fFN detection kits for preterm premature rupture of membranes and preterm labor diagnosis), and 慧安康® for nephrology products (ACR rapid analysis system for CKD/DKD screening). The portfolio also includes the Gen2 ITS intelligent testing system. All products are designed for clinical settings, hospitals, laboratories, and home use, with exports to over 200 countries and regions worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- 博唐平® (BoTangPing): 糖化血红蛋白检测系统产品线，用于糖尿病诊断和管理
- 泰安康® (TaiAnKang)
- 慧安康® (HuiAnKang)
Products and services
- BH60 High-Efficiency Liquid Chromatography HbA1c Analyzer Ion-exchange HPLC HbA1c analyzer with NGSP and IFCC dual certification, variant pattern recognition, 60 seconds per sample throughput, maximum 110 samples loading capacity, and CV≤1% intra/inter-batch precision. Intended for clinical laboratories and secondary/tertiary hospital use.
- Four-Channel Automated HbA1c Analyzer (全自动四通道糖化血红蛋白检测仪)
- Single-Channel Automated HbA1c Analyzer (全自动单通道糖化分析仪)
- A1C-EXP M13 Automated HbA1c Analyzer
- Handheld HbA1c Detector (手持式糖化血红蛋白检测仪 - 博唐平)
- GluCoA1c Combination Meter (血糖糖化检测仪)
- Blood Glucose Meter (血糖仪)
- Hospital Blood Glucose Management System (院内血糖检测系统)
- IGFBP-1 Detection Kit (胰岛素样生长因子结合蛋白-1检测试剂盒)
- fFN Detection Kit (胎儿纤维连接蛋白检测试剂盒)
- IGFBP-1/fFN Combination Detection Kit
- ACR Rapid Analysis System (ACR快速分析系统)
- Gen2 ITS (Intelligent Testing System)
- Android Smartphone Test Fixture (安卓智能手机测试工装)
Quantifiable outcome
- CV≤3% repeatability for handheld HbA1c analyzers; CV≤1% precision for BH60 ion exchange HPLC analyzer
- +4 more outcomes
Companies that use BioHermes
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles6 records
BioHermes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature6 records
BioHermes partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights5 records
BioHermes competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche offers HbA1c testing on cobas analyzers plus a broad diabetes diagnostics menu. As a diversified global IVD leader, Roche competes with BioHermes in tertiary hospital and reference lab segments with deeper menus, larger salesforces, and stronger international brand recognition.
- Mindray (迈瑞医疗): Mindray is a leading Chinese medical device and IVD major with broad hospital channel reach and an expanding diabetes/clinical chemistry portfolio. Comparable as a Chinese-domestic broad incumbent competing with BioHermes for hospital procurement budgets in overlapping departments.
- Abbott Diagnostics: Abbott offers a broad diabetes diagnostics portfolio including HbA1c testing on Architect/Alinity systems and the FreeStyle Libre CGM line. While not a specialist HbA1c analyzer vendor, Abbott competes with BioHermes across the diabetes testing continuum from laboratory to ambulatory settings, representing a broader incumbent threat.
Direct peers
- EKF Diagnostics: EKF Diagnostics manufactures the QuikRead HbA1c point-of-care device and offers HbA1c analyzers targeting primary care and emerging markets. Comparable to BioHermes in POC strategy, primary care/grassroots focus, and emerging-market distribution approach.
- ARKRAY: ARKRAY is a Japan-based IVD company specializing in diabetes diagnostics, including the HA-8180 HPLC HbA1c analyzer and handheld POC HbA1c devices. Directly comparable to BioHermes' BH60 and handheld HbA1c product lines, with similar focus on grassroots/POCT segments and Asian market presence.
- Tosoh Corporation: Tosoh's HLC-723 series of ion-exchange HPLC HbA1c analyzers are widely adopted in Asian, European, and US clinical laboratories. Closely comparable to BioHermes' BH60 in core technology (HPLC-based separation), target customer (clinical labs, tertiary hospitals), and high-throughput precision positioning.
- Bio-Rad Laboratories: Bio-Rad is a global leader in HbA1c testing through its Variant II ion-exchange HPLC analyzer line, with deep penetration in US and EU hospital and reference lab markets. Directly comparable to BioHermes' BH60 HPLC-based HbA1c analyzers in product category, target customers (clinical labs, hospitals), and core chromatography technology.
- Sinocare (三诺生物): Sinocare is a leading Chinese blood glucose and HbA1c monitoring company (金准系列 HbA1c analyzers, gold standard blood glucose meters) directly competing with BioHermes in Chinese grassroots hospitals, pharmacies, and consumer/home segments. Closely comparable in geography, target customers, and product category.
- Trinity Biotech: Trinity Biotech manufactures HbA1c analyzers (Premier) and boronate affinity-based instruments, directly competing with BioHermes' Botangping® system in both clinical chemistry and point-of-care HbA1c segments. Highly comparable in product offering, target customer base (hospitals, labs), and regulatory certification approach (NGSP/IFCC).
Emerging players
- HemoCue (Radiometer/Danaher): HemoCue specializes in point-of-care diagnostics including HbA1c measurement, competing with BioHermes' handheld and POC HbA1c analyzers in primary care and small-hospital settings. Comparable in POC focus and grassroots customer base, though with stronger presence in European markets.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioHermes social profiles
Digital presenceBioHermes compliance and trust
Trust signalCompliance7 records
BioHermes financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioHermes leadership team
Management profileNumber of profiles
BioHermes funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioHermes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioHermes
What does BioHermes do?
BioHermes manufactures and sells in-vitro diagnostic (IVD) instruments and reagents specializing in glycated hemoglobin (HbA1c) detection for diabetes management, plus obstetrics rapid test kits (IGFBP-1, fFN) for preterm labor and premature rupture of membranes diagnosis, and ACR (albumin-to-creatinine ratio) rapid analysis systems for nephrology/CKD screening. The company sells these analyzers and consumables to hospitals, primary healthcare institutions, third-party laboratories, and individual home users across China and 200+ international markets.
Is BioHermes a public or private company?
BioHermes is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioHermes founded?
BioHermes was founded in 2006. It employs 11 to 50 people.
Where is BioHermes based?
BioHermes is headquartered in Wuxi, China, in the Asia region.
How does BioHermes make money?
Two revenue lines are on record. In-vitro Diagnostic Instruments and Reagents Sales are the primary driver. The others are international Export Revenue.
Who are BioHermes's main competitors?
Broad incumbents on record are Roche Diagnostics, Mindray (迈瑞医疗) and Abbott Diagnostics. Direct peers are EKF Diagnostics, ARKRAY, Tosoh Corporation, Bio-Rad Laboratories, Sinocare (三诺生物) and Trinity Biotech. HemoCue (Radiometer/Danaher) is listed as an emerging player.
Does BioHermes have an API?
No public API is recorded for BioHermes.
What industry is BioHermes in?
BioHermes's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAAALAH, Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing), with a secondary code of HLAHAAAB, Hematology & Coagulation Diagnostics. Its NAICS code is 325413 and its SIC code is 3826.